Estimating Health-State Utility Values in Kidney Transplant Recipients and Waiting-List Patients Using the EQ-5D-5L-Reference-Cited by-同舟云学术

Estimating Health-State Utility Values in Kidney Transplant Recipients and Waiting-List Patients Using the EQ-5D-5L

Published:2017-07 Issue:7 Volume:20 Page:976-984
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Li Bernadette,Cairns John A.,Draper Heather,Dudley Christopher,Forsythe John L.,Johnson Rachel J.,Metcalfe Wendy,Oniscu Gabriel C.,Ravanan Rommel,Robb Matthew L.,Roderick Paul,Tomson Charles R.,Watson Christopher J.E.,Bradley J. Andrew

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference32 articles.

1. Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis;Liem;Value Health,2008

2. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments;Wyld;PLoS Med,2012

3. Is meta-analysis for utility values appropriate given the potential impact different elicitation methods have on values?;Peasgood;Pharmacoeconomics,2015

4. Access to Transplantation and Transplant Outcome Measures (ATTOM): study protocol of a UK wide, in-depth, prospective cohort analysis;Oniscu;BMJ Open,2016

5. Kidney transplantation in the elderly: a decision analysis;Jassal;J Am Soc Nephrol,2003

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validation of a Core Patient-Reported Outcome Measure for Life Participation in Kidney Transplant Recipients: the SONG Life Participation Instrument;Kidney International Reports;2024-01

3. Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait;Journal of Medical Economics;2023-02-14

4. Cost Utility Analysis of Dapagliflozin in Egyptian Patients with CKD from the Payer Perspective;Open Journal of Nephrology;2023

5. Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus;Advances in Therapy;2022-10-20